These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29966150)

  • 1. Effects of Concomitant Administration of Sodium Glucose Co-transporter 2 Inhibitor with Insulin on Hemoglobin A1c, Body Mass Index and Serum Lipid Profile in Japanese Type 2 Diabetic Patients.
    Kusunoki M; Natsume Y; Miyata T; Tsutsumi K; Oshida Y
    Drug Res (Stuttg); 2018 Dec; 68(12):669-672. PubMed ID: 29966150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Concomitant Administration of a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients with Type 2 Diabetes Showing Relatively Good Glycemic Control Under Treatment with a Sodium Glucose Co-Transporter 2 Inhibitor.
    Kusunoki M; Natsume Y; Miyata T; Tsutsumi K; Oshida Y
    Drug Res (Stuttg); 2018 Dec; 68(12):704-709. PubMed ID: 29966149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors.
    Lee JY; Cho Y; Lee M; Kim YJ; Lee YH; Lee BW; Cha BS; Kang ES
    Diabetes Metab J; 2019 Apr; 43(2):158-173. PubMed ID: 30688052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Additional Administration of a Selective Inhibitor of Sodium Glucose co-transporter-2 Inhibitor on the Glycemic Control in Japanese Type 2 Diabetes Mellitus Patients Receiving Treatment with a Dipeptidyl Peptidase-4 Inhibitor.
    Kusunoki M; Sato D; Sakazaki T; Miyata T; Tsutsumi K; Oshida Y
    Drug Res (Stuttg); 2020 Apr; 70(4):131-136. PubMed ID: 32164029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
    Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
    Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor.
    Feng X; Gu Q; Gao G; Yuan L; Li Q; Zhang Y
    Ann Endocrinol (Paris); 2020 Oct; 81(5):476-481. PubMed ID: 32822653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Predictors of the Hypoglycemic Effect of Sodium-Glucose Co-transporter-2 Inhibitors in Hyperuricemic Patients: A Retrospective Descriptive Observational Study.
    Hirai T; Kawagoe Y; Kei M; Ogawa R; Itoh T
    Biol Pharm Bull; 2020; 43(5):782-787. PubMed ID: 32378557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of sodium-glucose co-transporter-2 inhibitors in Chinese patients with type 2 diabetes mellitus.
    Chan WB
    Singapore Med J; 2019 Jun; 60(6):309-313. PubMed ID: 30402655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-world Clinical Practice.
    Díaz-Trastoy O; Villar-Taibo R; Sifontes-Dubón M; Mozo-Peñalver H; Bernabeu-Morón I; Cabezas-Agrícola JM; Muñoz-Leira V; Peinó-García R; Martís-Sueiro A; García-López JM; Martínez-Olmos MA
    Clin Ther; 2020 Feb; 42(2):e1-e12. PubMed ID: 32005534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
    Yagi S; Aihara KI; Kondo T; Kurahashi K; Yoshida S; Endo I; Fukuda D; Nakaya Y; Suwaki KI; Takeji T; Wada T; Salim HM; Hama S; Matsuura T; Ise T; Kusunose K; Yamaguchi K; Tobiume T; Yamada H; Soeki T; Wakatsuki T; Matsuhisa M; Shimabukuro M; Akaike M; Sata M
    Adv Ther; 2018 Jan; 35(1):124-134. PubMed ID: 29185199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of sodium glucose Co-transporter 2 inhibitor use on anthropometric measurements and blood glucose in obese and non-obese type 2 diabetic patients.
    Dedemen B; Duman TT; Dedemen MM; Aktas G
    Clin Nutr ESPEN; 2024 Oct; 63():515-519. PubMed ID: 39047870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).
    Terauchi Y; Tamura M; Senda M; Gunji R; Kaku K
    Diabetes Obes Metab; 2018 May; 20(5):1176-1185. PubMed ID: 29316236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.
    Katakami N; Mita T; Yoshii H; Shiraiwa T; Yasuda T; Okada Y; Torimoto K; Umayahara Y; Kaneto H; Osonoi T; Yamamoto T; Kuribayashi N; Maeda K; Yokoyama H; Kosugi K; Ohtoshi K; Hayashi I; Sumitani S; Tsugawa M; Ryomoto K; Taki H; Nakamura T; Kawashima S; Sato Y; Watada H; Shimomura I;
    Cardiovasc Diabetol; 2021 Jan; 20(1):4. PubMed ID: 33397376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m
    Danne T; Edelman S; Frias JP; Ampudia-Blasco FJ; Banks P; Jiang W; Davies MJ; Sawhney S
    Diabetes Obes Metab; 2021 Mar; 23(3):854-860. PubMed ID: 33289297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials.
    Yang Y; Pan H; Wang B; Chen S; Zhu H
    Chin Med Sci J; 2017 Apr; 32(1):22-7. PubMed ID: 28399981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.
    Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
    Intern Med; 2018 Aug; 57(15):2147-2156. PubMed ID: 29607968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
    Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world impact of glycated hemoglobin reduction on treatment intensification and glycated hemoglobin goal attainment in type 2 diabetes mellitus patients initiated on a sodium glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i).
    Brunton S; Rozjabek HM; Pilon D; Lafeuille MH; Kamstra R; Wynant W; Bookhart BK; Lefebvre P
    Curr Med Res Opin; 2019 Sep; 35(9):1607-1614. PubMed ID: 30964362
    [No Abstract]   [Full Text] [Related]  

  • 20. Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center.
    Calapkulu M; Cander S; Gul OO; Ersoy C
    Diabetes Metab Syndr; 2019; 13(2):1031-1034. PubMed ID: 31336439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.